Science&Humans, a digital health platform focused on hormone health, has secured $10.0 million in new investment capital. This funding round marks a significant milestone for the company as it aims to expand its reach and enhance its offerings in a critical area of wellness. The investment underscores growing confidence in the company's approach to addressing often overlooked health concerns related to hormonal balance.
The company specializes in providing scientifically proven treatments, products, and devices designed to manage hormone health. Science&Humans operates as an end-to-end digital platform, covering diagnostics, personalized treatments, and the convenient delivery of medications directly to customers' homes. Its mission is to address the historical under-diagnosis and under-treatment of hormone imbalance symptoms, which can significantly impact overall health, metabolism, mood, and sexual wellness as individuals age.
This capital infusion is expected to fuel Science&Humans' strategic growth initiatives. While specific allocation details were not disclosed, the funds will likely be directed towards scaling operations, further developing its technology platform, and potentially expanding its range of hormone health solutions. The investment positions Science&Humans to solidify its market presence and continue its work in making modern hormone treatments accessible.
Having already served over 10,000 customers and established itself as Canada’s largest hormone health platform, Science&Humans is poised for continued expansion. The company's focus remains on improving access to treatments for hormones, aging-well, longevity, and sexual wellness, leveraging its digital model to reach a broader audience and address a persistent gap in healthcare.
.png&w=3840&q=75)
